Pluriomics

About Pluriomics

Pluriomics, operating under the brand Ncardia, is a specialized biotechnology company that focuses on drug discovery solutions, particularly in the cardiovascular and neural sectors. The company leverages its expertise in induced pluripotent stem cells (iPSCs) to provide comprehensive services that aid pharmaceutical companies in the development and testing of new drugs.

Ncardia's primary clients are pharmaceutical and biotech companies engaged in drug discovery and development. These clients rely on Ncardia's advanced iPSC technologies to conduct robust efficacy and safety assays, which are tests that measure the effectiveness and safety of drug candidates. The company operates in the highly specialized market of iPSC-based drug discovery, which is a niche but rapidly growing segment within the broader pharmaceutical and biotechnology industries.

The business model of Ncardia is built around offering end-to-end drug discovery services. This includes disease modeling, manufacturing of iPSCs, assay development, and high-throughput phenotypic screening. Essentially, they provide a full suite of services that help their clients identify and validate new drug candidates more efficiently and accurately.

Ncardia makes money by charging for these specialized services. They offer custom solutions tailored to the specific needs of their clients, which can range from early-stage drug discovery to more advanced stages of drug development. Their revenue streams come from service contracts, custom research projects, and potentially licensing their proprietary technologies and assays.

In summary, Pluriomics (Ncardia) is a contract research organization that uses advanced stem cell technology to support drug discovery in the cardiovascular and neural fields. They serve pharmaceutical and biotech companies by providing comprehensive, customized solutions that enhance the efficiency and accuracy of drug development.